Understanding the mechanisms of PD-L1 degradation is essential for developing therapeutic strategies to enhance anti-tumor immunity and improve the effectiveness of immune checkpoint inhibitors (Figure 3) (81). This evidence concerns the gene CD274 and neoplasm.